Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.50 USD

29.50
26,896,912

+0.40 (1.37%)

Updated Jul 16, 2024 04:01 PM ET

Pre-Market: $29.32 -0.18 (-0.61%) 8:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 4.06% and 0.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?

by Sundeep Ganoria

Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as Innovation, M&A Pick Up

by Kinjel Shah

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.

Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Pfizer (PFE) reachead $29.10 at the closing of the latest trading day, reflecting a +0.62% change compared to its last close.

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PFE or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PFE vs. NVO: Which Stock Is the Better Value Option?

Ekta Bagri headshot

Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?

by Ekta Bagri

Bristol Myers (BMY) faces an uphill struggle as top drugs face challenges. We advise investors to steer clear for the time being.

Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study

by Zacks Equity Research

Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.

The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri

by Zacks Equity Research

Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri are part of the Zacks top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development

by Kinjel Shah

Eli Lilly (LLY) offers to acquire Morphic Therapeutics for $3.2 billion. Pfizer (PFE) selects a once-daily formulation of danuglipron for further development as a weight loss pill.

Sheraz Mian headshot

Top Analyst Reports for Danaher, Morgan Stanley & Pfizer

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Morgan Stanley (MS) and Pfizer Inc. (PFE), as well as two micro-cap stocks, Elite Pharmaceuticals, Inc. (ELTP) and Oil-Dri Corporation of America (ODC).

Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?

by Zacks Equity Research

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates make the stock attractive

Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

Pfizer (PFE) concluded the recent trading session at $27.93, signifying a -0.43% move from its prior day's close.

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

by Zacks Equity Research

Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.

Kinjel Shah headshot

Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?

by Kinjel Shah

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine

by Zacks Equity Research

If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.

CDC Narrows Age Recommendation for Use of RSV Vaccine

by Zacks Equity Research

The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.

Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

by Zacks Equity Research

Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.

Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data

by Zacks Equity Research

Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.

Pfizer (PFE) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Pfizer (PFE) closed at $27.99 in the latest trading session, marking a -1.3% move from the prior day.

Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe

by Zacks Equity Research

Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

by Zacks Equity Research

Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly

by Zacks Equity Research

Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.

Kinjel Shah headshot

Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now

by Kinjel Shah

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.